Silence Receives Notice of Allowance for US Patent Application | GenomeWeb

Silence Therapeutics said this week that it has received a notice of allowance from the US Patent and Trademark Office on a patent application covering its siRNA delivery technology.

According to Silence, the allowed claims relate to the company's AtuPlex technology. Specifically, they cover the proprietary lipid used in the delivery system. The company noted that the technology is being used in its phase I cancer drug Atu027, as well as certain other RNAi drug candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.